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LETTERS TO THE EDITOR
Selection or Work-Up
Bias: A Recurrent
Caveat in Evaluation of
New Diagnostic
Modalities
To the Editor:
I read with great interest the recent
manuscript by Ernst et al. on the compar-
ison of endobronchial ultrasound (EBUS)
versus mediastinoscopy (MS) and the
accompanying editorial.1,2 The authors
report a sensitivity of 87% for EBUS ver-
sus 68% for cervical MS and conclude
that “endobronchial ultrasound may be
preferred in the histologic sampling of
paratracheal and subcarinal mediastinal
adenopathy because the diagnostic yield
can surpass mediastinoscopy.”
The recently introduced minimally
invasive staging procedures—endoscopic
esophageal ultrasound and EBUS—repre-
sent promising staging and restaging
techniques for lung cancer although
their specific role in relation to invasive
techniques remains controversial and
has not been clearly established yet. Un-
fortunately, when these newer diagnos-
tic procedures are compared with the
more classic techniques as cervical MS,
certain biases repeatedly show-up in
most studies which lead to inaccurate
conclusions.3 Also the present study
clearly suffers from a so-called work-up
or selection bias where a new technique
is only applied in a specific, predefined
subset of patients in whom the diagnos-
tic yield is known to be very high. Pa-
tients evaluated for lung cancer were
first selected by computed tomography
scan, which is rather inaccurate for pri-
mary staging, and only patients with
enlarged lymph nodes in some specific
stations were included. The newer tech-
nique—EBUS—was only applied in
these pathologically enlarged lymph
nodes and only these stations were com-
pared with MS. No information is pro-
vided on the other lymph node stations
sampled at MS which were not evalu-
ated by EBUS; so, the reported sensitiv-
ity of EBUS is artificially high. More-
over, as in a previous comparative study,
only suboptimal results are present for
cervical MS.4,5 The latter study con-
cluded that esophageal ultrasound was
superior to MS, but sensitivity of MS
was only 24%. Although this study was
published in 2005, no further prospec-
tive studies were published confirming
these results. In a prospective study
from our institution comparing MS with
the findings on chest computed tomog-
raphy published in 1997, sensitivity of
cervical MS was 89% and for the sub-
carinal lymph node station seven, where
the largest disagreement was noted by
Ernst et al., sensitivity was 87%. Even
for repeat MS, sensitivity has been re-
ported to be higher than for the pri-
mary MS in the present study. Four
centers participated in this trial includ-
ing a total of 66 patients. There were
only three endoscopists performing
EBUS versus eight surgeons perform-
ing MS. In the methods section only a
very short paragraph is dedicated to
MS. What was the experience of the
surgeons performing MS? Were they
all thoracic surgeons? Were specific
guidelines followed? What are the overall
results for routine MS in each participat-
ing center? In fact, EBUS results in a
selected group of patients are com-
pared with a suboptimal performed
cervical MS, questioning the final
conclusion.
From its introduction MS has
been constantly criticized by radiolo-
gists, nuclear and invasive pulmonary
physicians. However, by providing
large tissue samples and a complete
mapping of the superior mediastinum,
it remains an invaluable tool for stag-
ing and restaging of lung cancer. The
value of minimally invasive techniques
still has to be demonstrated in prospective
studies with a clear design in which selec-
tion biases that artificially raise sensitivity,
are eliminated. The beginning of the end
of MS seems far away . . .
Paul E. Van Schil, MD, PhD
Department of Thoracic and
Vascular Surgery
Antwerp University Hospital
Belgium
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Rapid Detection of
Hotspot Mutations in
Epidermal Growth
Factor Receptor by
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Reaction Facilitates the
Management of
Non-small Cell Lung
Cancer
To the Editor:
Histopathologic diagnosis is criti-
cal for lung cancer treatment, but some-
times it could be challenging when the
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primary lesion is not easily accessible or
the biopsy fails to differentiate the histol-
ogy. Because recent studies have shown
that lung cancer, especially adenocarci-
noma, exclusively harbors hotspot mu-
tations in exon 18 to 21 of epidermal
growth factor receptors and cancer cells
with epidermal growth factor receptor
(EGFR) mutations are more likely to
be sensitive to tyrosine kinase inhibi-
tors than those without.1,2 Therefore,
using molecular technique to identify
these mutations in cancer cells has both
diagnostic and predictive value for lung
cancer.3 We report a case of lung ade-
nocarcinoma with vertebral metastases
whose diagnosis and treatment were
facilitated by the detection of EGFR
mutations.
A 54-year-old male nonsmoker
was admitted to our hospital because of
aggravating low back pain accompanied
by progressive weakness in right lower
extremity for 3 months and body weight
loss of 5 kg in 6 months. Magnetic
resonance imaging of the lumbar spine
showed lytic lesions in the L3–4 region,
together with a mass lesion in the left
upper lung on both chest radiograph and
computerized tomography. Carcinoem-
bryonic antigen level was elevated to
25.2 ng/ml. The patient then received
surgical decompression by laminectomy
and the surgical specimen was sent
for pathologic examination and for
screening of EGFR mutations. The
pathologic examination only revealed
necrotic tissue, without identifiable
cancer cells. Nevertheless, screening
of EGFR mutations by polymerase
chain reaction (PCR) revealed an exon
20 insertion, suggestive of primary
lung cancer (Figure 1A). Direct se-
quencing of the PCR product proved
the presence of a 15-nt insertion (Fig-
ure 1B). Subsequent computerized to-
mography-guided biopsy of the chest
lesion revealed adenocarcinoma with
the same insertion. The patient subse-
quently received local radiotherapy
and systemic chemotherapy.
This case illustrates the usefulness
of including routine EGFR mutation
screening to facilitate lung cancer diag-
nosis. Although the presence of EGFR
mutations in exon 19 and 21 indicates
the high response rates to tyrosine ki-
nase inhibitors with improved survival,
the presence of exon 20 mutations indi-
cates the resistance.2,4 Therefore, a
screening of EGFR mutations by con-
ventional DNA-based PCR methods
could greatly improve the diagnosis and
treatment design of lung cancer and
should be considered as a part of routine
pathologic examinations.
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FIGURE 1. Screening of EGFR mutations. Genomic DNA isolated from laminecto-
mized tissue and PCR was used to amplify exon 18 to 21 in EGFR. Mutations in
exon 18 were detected by direct sequencing and exon 19 deletions and exon 20
insertions were resolved by length differences on gel electrophoresis. Exon 21
L858R point mutations were identified by first digesting PCR product with MscI,
followed by gel electrophoresis. Mutant allele remains undigested after enzyme
treatment. A, Gel electrophoresis of PCR products for exon 19 to 21. C, cancer tis-
sue; N, normal control; CU, cancer, undigested; CD, cancer, digested; NU, normal,
undigested; and ND, normal, digested. Arrow, mutant band. B, Sequencing of
exon 20 mutant band. Underlined, inserted nucleotides. Primer sequences and de-
tailed PCR conditions are available on request.
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